Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus.

ABSTRACT: To date, there is no licensed vaccine for Middle East respiratory syndrome coronavirus (MERS-CoV). Therefore, MERS-CoV is one of the diseases targeted by the Coalition for Epidemic Preparedness Innovations (CEPI) vaccine development programs and has been classified as a priority disease by the World Health Organization (WHO). An important measure of vaccine immunogenicity and antibody functionality is the detection of virus-neutralizing antibodies. We have developed and optimized a microneutralization assay (MNA) using authentic MERS-CoV and standardized automatic counting of virus foci. Compared to our standard virus neutralization assay, the MNA showed improved sensitivity when analyzing 30 human sera with good correlation of results (Spearman's correlation coefficient r = 0.8917, p valu

SUBMITTER: Muller-Krauter H 

PROVIDER: S-EPMC11082005 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature